• Lilly reported interim findings from the Phase 3b ADlong open-label extension study of EBGLYSS (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis, and said the first-year results will be presented at the American Academy of Dermatology Annual Meeting.
• At up to four years of continuous treatment, 94% of patients achieved EASI-75 and 75% achieved EASI-90.
• In the same analysis, 68% reached IGA 0/1 and 78% reported Pruritus NRS ≤4.
• Lilly said 80% of patients achieved outcomes without topical corticosteroids, and 77% were on EBGLYSS monotherapy.
• In the first year of ADlong, treatment-related adverse events included conjunctivitis in 6.9% of patients and injection-site reactions in 0.6%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE20774) on March 27, 2026, and is solely responsible for the information contained therein.